PLGA nanofiber scaffolds conjugated with the antimicrobial peptide KR-12 simultaneously promoted bone stem cell differentiation (enhanced ALP, calcium, collagen, and bone marker expression) and inhibited MRSA and P. aeruginosa biofilm formation — addressing both infection and regeneration in one device.
Dual function: bone growth + MRSA biofilm inhibitionA single scaffold coated with the antimicrobial peptide KR-12 enhanced all measured bone formation markers in stem cells while simultaneously preventing biofilm formation by multidrug-resistant bacteria
What the researchers found
KR-12-functionalized PLGA nanofiber scaffolds demonstrated dual functionality. For bone regeneration, human bone marrow mesenchymal stem cells on these scaffolds showed enhanced alkaline phosphatase (ALP) activity, increased calcium and collagen deposition, and upregulated expression of key bone markers: collagen type I (COL1), osteopontin (OPN), and osteocalcin (OCN), confirmed by immunofluorescence staining.
For infection prevention, the scaffolds potently inhibited biofilm formation by both multidrug-resistant (MRSA, P. aeruginosa) and non-MDR (E. coli, S. aureus) bacteria. The peptide was covalently conjugated to the nanofibers via cold atmospheric plasma (CAP) treatment — a novel approach for KR-12/PLGA combination not previously reported.
Why it matters
Implant-associated infections affect up to 5% of orthopedic procedures and are devastating when they occur — often requiring implant removal, prolonged antibiotic courses, and revision surgery. Biofilm formation on implant surfaces makes these infections nearly impossible to treat with systemic antibiotics. A scaffold that simultaneously fights infection and promotes bone growth eliminates the conflict between anti-infection treatment (which can impair bone healing) and bone regeneration (which can be disrupted by infection) — two goals that have traditionally worked against each other.
How the study worked
PLGA electrospun nanofibers were fabricated by electrospinning and surface-treated with cold atmospheric plasma to enable covalent KR-12 conjugation. Surface characterization used SEM, contact angle measurements, FITC labeling, and FTIR spectroscopy. Osteogenic activity was assessed by culturing human bone marrow-derived mesenchymal stem cells on the scaffolds and measuring ALP activity, calcium/collagen deposition, bone gene expression (COL1, OPN, OCN), and immunofluorescence. Antibacterial and anti-biofilm activity was tested against MDR MRSA and P. aeruginosa, and non-MDR E. coli and S. aureus.
What this study cannot tell us
This is an in vitro study — the scaffolds have not been tested in animal bone defect models. The duration of antimicrobial activity from covalently bound KR-12 was not assessed long-term. The mechanical properties of the scaffolds and their suitability for load-bearing bone applications were not characterized. The cold atmospheric plasma treatment process may affect PLGA fiber properties. Clinical translation would require extensive in vivo testing, biocompatibility studies, and mechanical validation.
How to read the evidence
This is an in vitro biomaterials study with thorough scaffold characterization, cell culture osteogenic assessment, and antimicrobial testing. The covalent conjugation approach is novel and well-validated, but the absence of in vivo data limits the translational evidence.
When this study was published
Published in 2026, this is a very recent study at the forefront of peptide-functionalized biomaterials for bone tissue engineering.
The bigger picture
KR-12 is the minimal active sequence of LL-37, the human body's primary antimicrobial peptide. Its dual role — both antimicrobial and osteoinductive — makes it uniquely suited for bone tissue engineering. This study advances the field by achieving covalent conjugation (not just physical adsorption) to a clinically relevant biodegradable polymer, potentially providing longer-lasting antimicrobial activity. The approach aligns with the growing trend toward 'smart biomaterials' that actively participate in both infection prevention and tissue regeneration.
Questions still open
- How long does the anti-biofilm activity of covalently conjugated KR-12 persist — does it last throughout the critical early healing window?
- Can these KR-12-PLGA scaffolds support bone regeneration in animal models of infected bone defects?
- Would combining KR-12 with other osteoinductive factors (like BMP-2) produce synergistic bone regeneration while maintaining anti-biofilm activity?
Common questions
What is KR-12 and why use it for bone implants?
Why are biofilm infections on bone implants so hard to treat?
Read the original research
Plasma-Assisted KR-12 Conjugated PLGA Nanofibers With Dual Osteogenic and Biofilm-Inhibitory Activity.
Journal of biomedical materials research. Part A, 114(3), e70059
Citation
Pulat, Günnur; Bilgiç, Eda; Sezer, Buse. (2026). Plasma-Assisted KR-12 Conjugated PLGA Nanofibers With Dual Osteogenic and Biofilm-Inhibitory Activity.. Journal of biomedical materials research. Part A, 114(3), e70059. https://doi.org/10.1002/jbm.a.70059